Pharmaceutical Investing Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs
Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas
Pharmaceutical Investing Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006
Pharmaceutical Investing Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
Corvus Pharmaceuticals to Present Data on Lead Oral Checkpoint Inhibitor CPI-444 at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
